Literature DB >> 25893918

Matched Comparison of Two Different Biological Prostheses for Complete Supra-annular Aortic Valve Replacement.

Kathrin Fiegl1, Marcus-Andre Deutsch1, Ina-Christine Rondak2, Ruediger Lange1, Ralf Guenzinger1.   

Abstract

Objective The aim of this retrospective study was to evaluate the hemodynamic performance of the St. Jude Medical Trifecta (SJM Trifecta; St. Jude Medical, St Paul, Minnesota, United States) and the Carpentier-Edwards Perimount Magna Ease (CEPM Ease; Edwards Lifesciences, Irvine, California, United States) bioprostheses early postoperative and at 1 year. Methods From October 2007 to October 2008, a total of 61 consecutive patients underwent aortic valve replacement (AVR) with the CEPM Ease prosthesis. From a prospective cohort of 201 patients (March 2011 to January 2012) who received AVR with the SJM Trifecta valve, a matched group of 51 patients was selected. Matching was conducted 1:1 by ejection fraction, gender, age, and body surface area. A Hegar dilator was used to define the aortic tissue annulus diameter. Data were grouped on the basis of the patient's tissue annulus diameter (≤22 mm; 23-24 mm; ≥25 mm). Results Early postoperative and at 1 year mean pressure gradients (MPGs) in the various groups ranged from 7.2 ± 4.6 to 7.1 ± 2.4 mm Hg and from 10.0 ± 4.3 to 8.0 ± 2.8 mm Hg in the SJM Trifecta group and from 18.0 ± 5.0 to 12.1 ± 3.6 mm Hg and from 17.7 ± 4.5 to 11.8 ± 3.2 mm Hg in the CEPM Ease group, respectively. Likewise, effective orifice areas (EOAs) ranged from 1.7 ± 0.5 to 2.0 ± 0.5 cm(2) and from 1.5 ± 0.3 to 1.7 ± 0.4 cm(2) in the SJM Trifecta group and from 1.3 ± 0.5 to 1.9 ± 0.5 cm(2) and from 1.2 ± 0.3 to 1.8 ± 0.3 cm(2) in the CEPM Ease group, respectively. A marked left ventricular mass (LVM) regression across all annulus sizes was noted in both groups. Severe patient-prosthesis mismatch (PPM) was infrequent overall. Conclusion The SJM Trifecta valve showed lower MPGs early postoperative and at 1 year as well as higher EOA and effective orifice area index early postoperative. No significant differences were detected with regard to LVM regression and PPM. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2015        PMID: 25893918     DOI: 10.1055/s-0035-1548744

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  5 in total

1.  Clinical outcome and hemodynamic performance of St. Jude Trifecta aortic prosthesis: short-term follow-up and risk factors analysis.

Authors:  Paolo Nardi; Calogera Pisano; Fabio Bertoldo; Sara Rita Vacirca; Monica Greci; Carlo Bassano; Antonio Scafuri; Antonio Pellegrino; Giovanni Ruvolo
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

2.  Safety, effectiveness and haemodynamic performance of a new stented aortic valve bioprosthesis.

Authors:  Robert J M Klautz; A Pieter Kappetein; Rüdiger Lange; Francois Dagenais; Louis Labrousse; Vinayak Bapat; Michael Moront; Martin Misfeld; Cathy Zeng; Joseph F Sabik Iii
Journal:  Eur J Cardiothorac Surg       Date:  2017-09-01       Impact factor: 4.191

3.  The Prognostic Significance of Patient-Prosthesis Mismatch after Aortic Valve Replacement.

Authors:  Paolo Nardi; Marco Russo; Guglielmo Saitto; Giovanni Ruvolo
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2018-06-05

4.  Clinical outcomes and hemodynamic performance of Dafodil™ aortic and mitral pericardial bioprosthesis: 1-year results from Dafodil-1 first-in-human trial.

Authors:  C S Hiremath; Anil R Jain; Anurag Garg; Nirmal Gupta; Yugal K Mishra; Zile Singh Meharwal; Nityanand Thakur; Atul A Maslekar; Naman Shastri
Journal:  J Cardiothorac Surg       Date:  2020-06-15       Impact factor: 1.637

5.  A Retrospective Comparison of Hemodynamic and Clinical Outcomes between Two Differently Designed Aortic Bioprostheses for Small Aortic Annuli.

Authors:  Do Jung Kim; Sak Lee; Hyun-Chel Joo; Young-Nam Youn; Kyung-Jong Yoo; Seung Hyun Lee
Journal:  J Clin Med       Date:  2021-03-04       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.